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latelet apoptosis and the role of platelet-derived microparticles on different pathophysiological conditions. It also touches upon the effects
f biologicals on platelets, and discusses the need to overcome the adverse effects of pro-apoptotic drugs through auxiliary therapy.
 2014 Elsevier Ireland Ltd. All rights reserved.
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.  Introduction
Platelets were once considered mere mediators of
emostasis and thrombosis. However, rigorous research in
he field of platelet biology gave a new insight into their
ynamic and versatile characteristics. It is amazing that these
eemingly simple anuclear cells, which are unique to mam-
als, have such a vast array of physiological functions [1].
hey play crucial roles in pathophysiological conditions
ncluding wound healing, inflammation, cardiovascular dis-
ases (CVDs), diabetes, arthritis, Alzheimer’s disease (AD),
ngiogenesis and metastasis. Till two decades ago, it was
ot known how exactly their numbers is controlled or how
hey undergo death. Recent reports prove beyond doubt that
latelets do undergo programmed cell death via apoptosis.
part from cellular senescence, platelet apoptosis is also
riggered by various stimuli including chemical agonists
e.g., thrombin, collagen, ADP, hydrogen peroxide, arachi-
onic acid, epinephrine, calcium ionophore-A23187, etc.),
xidative stress-induced pathological conditions (e.g., hyper-
ipidemia, Kawasaki disease, Bernard–Soulier syndrome,
ltered cardiac functions, type-2 diabetes and chronic ure-
ia) and physical factors (e.g., hyperthermia, platelet storage
nder standard banking conditions, shear stress) [2].
Bone marrow megakaryocytes undergo apoptosis de
acto to release platelets. As such, platelets possess the
ellular machinery (which is derived from their parent cells)
equired for normal functioning. This implies that they also
ndergo apoptosis like any other nucleated cell, except for
he nuclear apoptotic events. However, till date there is
trong evidence only for the intrinsic apoptotic pathway
nd very few studies on the extrinsic pathway in platelets.
he former occurs through mitochondrial dysfunction in
esponse to stress. Apoptotic platelets display elevated
evels of reactive oxygen species (ROS), calcium (Ca2+),
ytochrome c, apoptotic protease-activating factor-1 (Apaf1)
nd caspases-9 and -3, which are all considered markers
f apoptosis. In addition, platelets undergoing apoptosis
lso express surface markers such as phosphatidylserine
PS) (Fig. 1) [3]. Recent reports suggest the involvement
f cell signaling pathways such as, p38 MAPK/cPLA2,
I3K, extracellular signal-regulated protein kinase (ERK)
nd c-Jun NH2-terminal kinase (JNK) in apoptotic platelets
4–7]. Further, there are various lines of evidence sug-Please cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
esting the existence of extrinsic apoptotic pathway in
latelets, but none decisively prove it. For instance, though
he presence of TNF-  (a prominent cytokine regulating
xtrinsic apoptotic pathway) in platelets is controversial,
r
t
d
c; Cancer
ccumulation and secretion of a range of TNF--related
igands like Fas-L, TRAIL, TWEAK and LIGHT, is observed
8]. Stored platelets are also found to express mRNA and
roenzyme for caspases-8 and -10, mRNA for death recep-
ors such as, DR3, DR4, DR5, TRAIL, TNF receptor p55,
nd RIP, as well as elevated concentration of TNF  [9].
oreover, caspase-8 activation in platelets stimulated with
PEN and resveratrol was also reported [10,11].
When the rate of platelet apoptosis exceeds the normal
hysiological level, it may have far-reaching consequences:
i) reduced platelet count (thrombocytopenia) leading to
leeding disorders; (ii) generation of microparticles (MPs),
hich play a major role in the propagation of various patho-
ogical conditions such as, CVDs, cancer, type-2 diabetes
nd arthritis [12]. Platelet-derived MPs (PMPs) constitute
round 80% of circulating MPs. A study by Berckmans
t al. determined the concentration of MPs of different cel-
ular origin in fresh blood samples via flowcytometry to
e 237 ×  106/L (platelet-derived), 28 ×  106/L (erythrocytes-
erived), 46 × 106/L (granulocyte-derived) and 64 ×  106/L
endothelial cell-derived) [13]. MPs are vesicle-like struc-
ures surrounded by plasma membrane bilayer enclosing
nzymes, transcription factors and mRNA [14,15]. Apop-
otic platelets shed MPs via dynamic membrane blebbing
hat is driven by the contractile force of cytoskeletal struc-
ures actin–myosin [16]. Activated Rho-associated kinase
ugments the actin–myosin force generation. The shed MPs
ontain a surfeit of biomolecules including proteins (sig-
al proteins, receptors, cytoskeleton, and effector proteins),
ipids, and nucleic acids. They express several surface anti-
ens such as, GpIb, PECAM-1, GpIIb-IIIa, P-selectin, CD
3, CD41a, and CD 61 [17]. However, the surface protein
ontent may be different from that of the plasma membrane
f the parent cell, since the inclusion of protein molecules
nto MPs can be selective and regulated by the stimuli from
pecific agonists or microenvironments of the parental cells
18].
The present review mainly focuses on the impact of
latelet apoptosis and the role of MPs on different patho-
ogical conditions. Owing to the extremely sensitive nature
f platelets, they are very much vulnerable to therapeutic
rugs in the circulation. The surfacing of recent reports
f commonly used therapeutic drugs provoking platelet
poptosis is of serious concern, considering the prominent platelet apoptosis and human diseases: An outlook. Crit Rev
02
ole played by platelets in health and disease. Thereby,
he review also touches upon the effects of therapeutic
rugs on platelet apoptosis and MP generation, and their
linical consequences. Finally, the need to overcome the
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dverse effects of pro-apoptotic drugs through auxiliary
herapy is stressed upon, wherein the biologicals that display
nti-apoptotic effects on platelets are discussed.
.  Physiological  relevance  of  platelets  and
latelet-derived  microparticle  generation
Platelets are essentially destined to curb bleeding; nev-
rtheless they have diverse functions beyond hemostasis
nd thrombosis. They recruit leukocytes and progenitor
ells to vascular injury and inflammation sites, secrete pro-
nflammatory, anti-inflammatory and angiogenic factors and
Ps into the circulation, and also stimulate thrombin gener-
tion. Their ability to store and release bioactive molecules
akes them key functional modulators of other cells. Platelets
lso generate lipid-derived mediators such as thromboxane
2, and participate in transcellular metabolism as well. They
re capable of accomplishing extranuclear translation of pro-
eins that include IL-1  and tissue factor, which connect
emostasis with inflammation [1]. Platelets also have cru-
ial roles in host defense, response to injury, and immune
urveillance by acting as circulating sensors that link immune
esponses to wound healing. Indeed, platelets co-ordinate thePlease cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
hole process of tissue repair by eliciting an inflammatory
athway that involves extracellular matrix remodeling, cell
igration, proliferation and differentiation, and angiogene-
is [8,19]. They release cytokines, chemokines, and growth
t
s
nf platelet apoptosis.
actors including SDF-1 and HGF that mediate recruitment,
roliferation and activation of the cells that are involved
n wound healing such as, fibroblasts, neutrophils, mono-
ytes, smooth muscle cells and mesenchymal stem cells.
latelets also maintain the balance between cell death and sur-
ival by releasing both proapoptotic (Fas-L, CD40L, TRAIL,
WEAK and LIGHT) and antiapoptotic (hepatocyte growth
actor, stromal-derived growth factor-1, serotonin, adenosine
iphosphate and sphingosine-1-phosphate) factors, which
n turn influence the pathophysiology of damaged tissue
8]. Recently, platelets were reported to safeguard the vas-
ular integrity by supporting the semi-permeable barrier
unction of the resting endothelium [20]. Thus, discrep-
ncies in platelet apoptosis rate might have far reaching
onsequences than was thought earlier. Drop in platelet
ount might not only lead to bleeding disorders, but also
ffect the processes of inflammation, tissue repair, tran-
cellular metabolism, immune surveillance, along with loss
f vascular integrity. Thus, the several studies that have
eported thrombocytopenia as a secondary complication in
 treatment regimen should not be taken lightly as just a
ondition with low platelet count. Thrombocytopenia might
e the beginning of various other health problems caused
y the altered biological functions that involve platelets
s discussed above. This aspect not only calls for fur- platelet apoptosis and human diseases: An outlook. Crit Rev
02
her research but also make amendments in the treatment
trategies in drugs that are known to cause thrombocytope-
ia.
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with coronary artery damage and other cardiovascular com-ological and pathological events.
Further, PMPs that were long been considered inert
platelet dust’ are now reported to wield their effects on
ther cells as well. Currently, PMPs are deemed as markers
hat indicate the balance between cell proliferation and death.
ecause PMPs express procoagulant PS on their surface, a
ajor bulk of them is considered to arbitrate hemostasis under
hysiologic conditions. Besides their marker functions, MPs
ave a significant role as vectors in the transcellular com-
unication as they possess various types of receptors and
ioactive substances on their surface including cytokines,
ignal proteins and nucleic acids, in addition to mRNA and
iRNA [14,21]. They exchange biological information with
arget cells either via surface-expressed ligands or by trans-
orting surface receptors from one cell to the other. MPs also
ave the capacity to reprogram target cells via attaching or
using and delivering cytoplasmic proteins and RNA to the
ells. Further, PMPs have been shown to respond to signals
hat elicit antibody synthesis and alter lymphocyte activities,
nd thus activate adaptive immune cells in the particular tis-
ue [22]. PMPs are also involved in tissue repair. They control
poptosis in endothelial and smooth muscle cells, and also
rovide survival signals to monocytic, endothelial and neu-
al stem cells [8]. Thus, MPs have acquired an exceptional
tatus in human physiology of late, and their role in the main-Please cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
enance of homeostasis and normal health cannot be ignored
Fig. 2). Hence, it is imperative to monitor the MP levels in
atients undergoing treatment with drugs that are known to
p
p
lology/Hematology xxx (2014) xxx–xxx
ause thrombocytopenia. Unfortunately, the importance of
Ps in the healing process and their side-effects are not yet
ecognized as a serious threat by the medical fraternity. More-
ver, simple and effective methods to measure MPs are not
et popularized.
.  Platelet  apoptosis  and  microparticles  –  role  in
athological conditions
Since, platelets and PMPs play such a critical role in nor-
al human physiology, it is quite obvious that disturbances
n their numbers and functions might instigate disastrous
athological outcomes (Fig. 3). Platelet response to vari-
us disease conditions depends on the surface active markers
e.g., CD36, CD41, CD42a, CD42b, and CD61) and secre-
ory biomolecules [23]. Platelets are known to interfere with
he signaling and expression of these molecules in different
isease pathologies, some of which are discussed below.
.1.  Bleeding  disorders
Thrombocytopenia is a condition wherein the platelet
ount slumps to 100,000 platelets/L of blood, the nor-
al range being 150,000–450,000/L of blood. In severe
ases the platelet count drops below 10,000/L leading
o a greater risk of bleeding. Thrombocytopenia seems to
e the direct and most obvious consequence of elevated
ate of platelet apoptosis. More than 200 drugs reportedly
ause immune thrombocytopenia, e.g., antibiotics (rifampin,
ulfamethoxazole, vancomycin, sulfonamides, linezolid,
tc.), anticonvulsants (carbamazepine, phenytoin, valproic
cid), RGD mimetic agents (eptifibatide and tirofiban),
nti-inflammatory drugs (acetaminophen, diclofenac, qui-
ine), antineoplastics (interferon-), cardioprotective drugs
eptifibatide, quinidine, tirofiban), antihypertensive drugs
methyldopa), as well as antidiabetic drugs (chlorpropamide)
12]. However, barring few it is not known whether all these
rugs induce platelet apoptosis. Bernard–Soulier syndrome
BSS) is another bleeding disorder, which is characterized
y abnormally large platelets that have increased PS surface
xposure in the resting state, and reduced rate of survival in
he circulation. Activated BSS platelets have been reported to
ndergo apoptosis-like events, with PS exposure and MP pro-
uction being enhanced, resulting in their shortened survival,
s well as affecting thrombin generation [24].
.2.  Cardiovascular  disorders
Kawasaki disease (KD), which is characterized by inflam-
atory acute febrile vasculitis, is associated with oxidative
tress and defective platelet apoptosis. KD is associated platelet apoptosis and human diseases: An outlook. Crit Rev
02
lications. PS-exposing platelets are known to exert a
ro-coagulant activity leading to increased risk of vascu-
ar complications in KD [25]. In hyperlipidemia (which is
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MFig. 3. Different human pathological conditions/disorders responsibl
 classical cardiovascular risk factor), some platelets are
eported to be in an activated state in circulation, and undergo
arly apoptosis [26]. Moreover, activated platelets and circu-
ating PMPs possess active surface area with procoagulant
minophospholipids, which support the assembly of the
oagulation cascade enzymes [27,28]. Because PMPs express
rocoagulant PS on their surface, there are possibilities of
eviation toward the pathogenesis of arterial thrombotic and
hromboembolic complications [22,29]. Acute coronary syn-
rome is initiated by the erosion and rupture of an atheroscle-
otic plaque, which disturbs the subendothelial protein matrix
llowing platelet-adhesion molecules like vWF factor and
ollagen to interact with circulating platelets. This leads to
latelet activation, shape change and release of storage gran-
les containing platelet agonists such as, ADP and TxA2,
nd shape change of platelet fibrinogen receptor GPIIb/IIIa.
esides, already-activated platelets and the released PMPs
rovide a new prothrombotic interface for fibrin, blood cells,
nd a growing thrombus resulting in narrowing of the vessel.
he elevated shear stress due to vascular narrowing, pro-
ract this process by supporting further platelet activation and
MP release. Ultimately, an occlusive thrombus forms and
atients go through grievous events. The PMPs contain recep-
ors (GPIIb/IIIa, Ib, Ia, and IIa) for platelet–subendothelium
ttachment, and P-selectin for platelet–leukocyte interac-
ions and inflammatory response [30]. Several studies have
videnced that circulating MPs might serve as potential prog-
ostic markers for atherosclerotic vascular disease. PMPs that
xpress P-selectin and CD63 on their surface are a sign of
latelet activation in peripheral arterial disease and myocar-Please cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
ial infarction (MI). A recent study demonstrated enhanced
evels of PMPs in survivors of MI. It was shown that there
s a considerable connection of large PMPs with plasma
s
f
T
atelet derived microparticle generation and altered platelet functions.
hrombin–antithrombin complexes and soluble CD40 ligand
n MI patients. Further, it has also been shown that interior
nd exterior diameters of carotid artery correlate inversely
ith circulatory MPs concentration [22].
.3.  Cancer
The involvement of high PMP levels in cancer metas-
asis cannot be ignored because it is linked to belligerent
umors and reduced response to treatment [31]. PMPs are
eported to promote angiogenesis (which involves propaga-
ion, endurance, migration, and tube formation of human
mbilical vein endothelial cells) during tumor growth via
he combined action of vascular endothelial growth factor
VEGF), fibroblast growth factor-2 (FGF-2), and a lipid fac-
or [32]. The pro-angiogenic effect of PMP is brought about
y PI3-kinase and ERK pathways. It is thought that the PMP
oncentration at the sites of tumors may be unusually high.
n gastric cancer, PMP levels are better forecasters of metas-
asis than plasma levels of IL-6, RANTES, and VEGF [33].
MPs can also trigger the secretion of matrix metallopro-
einase MMP-2 in prostate cancer cells, promoting tumor
nvasiveness by their easy passage through collagen, a chief
onstituent of the extracellular matrix [34]. Thereby, the gen-
ration of PMPs over an extended period can be lethal, and
t is imperative to assess their count not only during disease
onditions but also during chemotherapy. In fact, it has been
eported that chemotherapy can cause platelet activation and
P generation, which in turn enhances the risk of thrombo- platelet apoptosis and human diseases: An outlook. Crit Rev
02
is. The MPs express adhesion molecules and release growth
actors and MMPs, all of which are essential for angiogenesis.
hese MPs interact with tumor cells and their environment,
nd further aid tumor growth. PMPs play a role in intercellular
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ross-talk and express various proteins on their surface,
ncluding platelet–endothelium attachment receptors (CD41,
D61 and CD62), G-protein receptors (CXCR4 and PAR-1),
ytokine receptors (TNF-RI, TNF-RII, CD95) and ligands
CD40L and PF-4), all of which can be transferred to the sur-
ace of tumor cells. Moreover, PMPs elicit mRNA expression
f angiogenic factors such as MMP-9, vascular endothelial
rowth factor, hepatocyte growth factor and IL-8 [35].
.4.  Malaria
Malarial infection is associated with thrombocytopenia,
s a result of shortened platelet lifespan. Thrombocytopenia
s found to be associated with a concurrent increase in the
umber of MPs in plasma. Activated platelets and MPs are
eported to play crucial roles in altering the blood–brain bar-
ier leading to severe form of malaria called cerebral malaria
36].
.5.  Arthritis
Rheumatoid arthritis (RA) is an incapacitating systemic
utoimmune inflammatory disease which mainly afflicts the
ynovial joints by evoking inflammation, and is character-
zed by immune cell recruitment and blood vessel dilation.
t has been reported that platelets accumulate in the joints of
A patients and that elevated numbers of PMPs are found
n their synovial fluid. Boilard et al. explored the involve-
ent of platelets in RA and demonstrated the presence of
MPs in the synovial fluid from the patients. Further, the
uthors showed the pro-inflammatory nature of PMPs via
he elicitation of cytokine responses (IL-1) from synovial
broblasts [37]. Detailed studies have revealed that colla-
en receptor GP-VI and its associated gamma chain of the
c receptor play a key role in eliciting PMP production in
rthritis pathophysiology. Further, fibroblast-like cells lining
he joint cavity trigger the shedding of PMP. Consequently,
he released PMPs interact with and activate fibroblast-like
ynoviocytes (FLS), which are important effector cells that
ediate both immune activation and joint destruction. The
timulated FLS bring about inflammatory cytokine responses
ia IL-1. Thereby, the IL-1 packaged into the PMPs seems
o play a principal role in amplifying inflammation. The ele-
ated level of PMPs in RA patients hints at their possible
ole in the progression of CVDs as well. RA patients are
ore susceptible to cardiovascular mortality, suggesting its
ssociation with the degree of inflammation. These reports
ut forward that PMPs might be the culprits involved in the
nflammatory and thromboembolic processes in RA patients
38].
.6.  DiabetesPlease cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
Diabetes mellitus (DM) patients are reported with platelet
yper-reactivity and increased platelet activation due to a
ultitude of factors such as hyper-secretion of insulin,
a
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yperglycemia, hyperlipidemia, oxidative stress, endothelial
ysfunction, and inflammatory condition. Hyperglycemia,
he basic characteristic feature of DM can cause increased
latelet reactivity and platelet activation as indicated by mark-
rs such as soluble P-selectin and CD40-ligand, which in turn
ight be due to protein kinase C (PKC) activation, a transduc-
ion pathway regulator of proaggregatory platelet agonists.
latelets from DM patients also exhibit short-term activa-
ion of the calcium-sensitive PKC  isoenzyme. Moreover,
he advanced glycation end products (AGEs) that are pro-
uced in excess in DM patients can cause PS externalization
n platelets leading to surface clotting factor activation, thus
ugmenting the thrombogenic state. The surface membrane
roteins also undergo enhanced glycation, which causes
ecreased membrane fluidity and increased platelet sensi-
ivity to agonists. DM patients have evidences of increased
xidative stress and inflammation as well [39]. Cohen et al.
eported that there is a drastic increase in thrombin activity
n the type 2 diabetic blood along with a significant increase
n PMPs. Furthermore, increased activities of caspases-3, -
, and -8 were also reported. Thus, it was conjectured that
he increased thrombin activity, PMP formation and caspase
ctivity together may contribute to the hypercoagulability
f diabetic blood. The study highlighted the link between
iabetic platelets and coagulation proteins that lead to pro-
hrombotic condition and validates the increased risk of
hromboembolic events in diabetic population [40]. PMPs
ere also reported to promote the expression of adhesion
olecules in monocytes and endothelial cells and therefore, it
ppears that they might even participate in the development of
therosclerosis in diabetics [41]. Furthermore, a recent study
ncovered the molecular pathway for platelet mitochondrial
amage in DM, wherein it was shown that hyperglycemia
eads to activation of aldose reductase ensuing in ROS gen-
ration, with consequent increase in p53 phosphorylation.
hese events were reported to cause loss of function and
amage to mitochondria, mitochondrial membrane poten-
ial dissipation, cytochrome c release, caspase-3 activation
nd PS exposure, thus resulting in platelet apoptosis [42].
lthough this study highlights the potential of aldose reduc-
ase inhibitors in DM treatment, it does not dwell into the
spect of aldose reductase-induced PMP generation in DM
nd its consequences.
.7.  Hyperthermia  and  dengue
Hyperthermia-related ailments such as dengue fever and
eatstroke are often associated with hemorrhage and reduced
latelet count. Therefore, Wang et al. investigated the effect
f hyperthermia on platelet physiology and found that
yperthermia triggers apoptotic events in platelets, including
m depolarization, caspase-3-dependent gelsolin cleav- platelet apoptosis and human diseases: An outlook. Crit Rev
02
ge and PS exposure, in addition to shedding of platelet
lycoprotein Ib  ectodomain [43]. Further, it was reported
hat mitochondrial ROS play a vital role in hyperthermia-
nduced platelet apoptosis, and that the decrease in platelet
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anganese superoxide dismutase activity might probably be
esponsible for the enhanced ROS levels in hyperthermia-
nduced platelets [44]. In a more recent study it was reported
hat in the course of dengue infection activated and apoptotic
latelets aggregate with monocytes and trigger specific
ytokine responses including the production and secretion
f IL-1b, IL-8, IL-10, and MCP-1 that may play a role in
he disease pathogenesis [45]. Though the role of platelets
n monocyte responses was clearly demonstrated in this
tudy, the possibility of PMS interacting with monocytes to
urther aggravate the inflammatory and immunomodulatory
eactions during dengue infection needs further investigation.
.8.  Alzheimer’s  disease
Alzheimer’s disease (AD) is an age-related neurode-
enerative condition characterized by the cerebral amyloid
ngiopathy (CAA), which involves the deposition of neu-
otoxic amyloid-  (A) plaque in brain parenchyma and
erebral blood vessels. Platelets contain the enzymatic
achinery to produce A  peptides; therefore, platelets are
ot only acknowledged as ex  vivo  model to explore the patho-
hysiology of AD, but also regarded as biomarkers for the
nitial diagnosis of AD [46]. A recent study by Gowert et al.
emonstrated that A-treated platelets exhibit apoptosis-like
vents including ROS generation, cytosolic Ca2+ activity,
itochondrial membrane depolarization, caspase-3 activa-
ion, cell shrinkage and PS externalization. It also showed
he vital role played by platelets in the development of CAA
ia release and modulation of A  into soluble fibrillar struc-
ures that were absorbed by apoptotic platelets. These events
nhanced platelet adhesion and accumulation at amyloid
eposits of cerebral vessels leading to thrombus formation
nd vessel occlusion, which are decisive for strokes in AD
atients [47]. However, the study does not probe the role of
MPs released from A-induced apoptotic platelets in the
athophysiology of AD.
.  Effect  of  pro-apoptotic  biologicals  on  platelets
Numerous studies of late have reported drug-induced
latelet apoptosis, a fact that was not known till a decade ago.
t present, various commonly used biologicals such as, mela-
onin, vancomycin, balhimycin, cisplatin, arsenic trioxide,
spirin, resveratrol, sesamol, dibucaine, andrographolide,
ossypol and carmustine are reported to elicit platelet apo-
tosis (Table 1) [6,7,11,12,48–52].
.  Platelet  anti-apoptotic  biologicals  and  their
pplication  in  auxiliary  therapyPlease cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
Even though numerous studies that have demonstrated
he wide array of protective efficacies of phytochemicals,
here are only two reports hitherto suggesting the platelet
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nti-apoptotic effects viz. cinnamtannin B1 and crocin. Cin-
amtannin B1 (CTB), a proanthocyanidin is found in many
pecies such as Laurus  nobilis  L. and Cinnamomum  verum.
roanthocyanidins including CTB have been widely reported
o display anticancer property via selective proapoptotic
ction in a wide range of cancer cell lines at the same
ime exerting antiapoptotic effects on healthy cells. Bouaziz
t al. investigated the effects of CTB on platelets and found
hat it impaired thrombin-evoked activation of caspase-3
nd -9 as well as their translocation to the cytoskeleton.
TB also inhibited thrombin-induced PS externalization and
ndogenous generation of H2O2, as well as H2O2-induced
aspase activation and PS exposure. The concentration of
TB used was similar to that used to induce apoptosis in
ancer cells [53]. Crocin is a carotenoid found in the stigma
f flowers of Crocus  sativus  L. (saffron). Crocin report-
dly possesses various health-promoting properties such as,
nticarcinogenic, antihyperlipidemic, antiarthritic and hep-
toprotective properties. Thushara et al. demonstrated that
rocin protects platelets from oxidative stress-induced apo-
tosis. It ameliorates various events of the H2O2-induced
ntrinsic apoptotic pathway including m  depolarization,
ytochrome c translocation, caspases 9 and 3 activation, PS
crambling, ROS generation and Ca2+ mobilization. Besides,
t was also found to inhibit agonist-induced platelet aggrega-
ion [54].
. Future  directions  and  conclusion
Platelets are now known to affect a wide array of
hysiological and pathological processes. Moreover, the
latelet-derived MPs under normal physiological status
re also known to play pivotal roles in a wide array of
hysiological functions and also aid in the maintenance of
omeostasis. The sensitive nature of platelets makes them
asily susceptible to various stimuli that can trigger apoptosis
t an exacerbated rate. This can result in severe reduction
f platelet count and thus affect the normal physiological
rocesses that involve platelets. Several scientific studies of
ate, have reported the pro-apoptotic tendency of commonly
sed biologicals. Besides, the excess PMPs that are produced
n the melee may have consequences of pathological order.
ith their rich content of cytosolic and surface molecules,
hich include a wide variety of cytokines and growth
actors, PMPs are capable of simultaneously triggering
ultiple signaling systems and thus when they are produced
n excess can have off-shoot reactions as well [55]. This may
esult in a vicious cycle wherein a platelet-proapoptotic drug
sed to treat one disease, which for the time-being might
ure the condition, but may later cause the re-emergence
f the same disease with stronger symptoms or may lead platelet apoptosis and human diseases: An outlook. Crit Rev
02
o another disease. Obviously, the system is subjected to
ore drugs, resulting in more stress. For instance, there
re several reports of recurrence of tumor at same sight
r at different one, increased risk of CVDs in arthritis and
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Table 1
List of biologicals that induce platelet apoptosis and their respective mechanism of action.
Biological Therapeutic indications Reported pro-apoptotic events in platelets
Vancomycin In the treatment of gram-positive penicillin-resistant infections,
bacterial endocarditis in penicillin-allergic patients, MRSA and
medical device-associated infections
Phospholipid scrambling, PS externalization, decrease in
platelet volumes, increase in intracellular Ca2+, m
depolarization, ceramide formation, and caspase-3 activity
Balhimycin Treatment of MRSA Cell shrinkage, cell membrane scrambling, increase in
intracellular Ca2+, ceramide formation, m depolarization
and caspase-3 activity
Cisplatin Treatment of tumors of the brain, breast, cervix, liver, lungs,
head and neck, ovaries, testes etc. as well as osteosarcoma,
melanoma, neuroblastoma and non-Hodgkin’s lymphoma
ROS production, up-regulation of proapoptotic Bax and Bak,
and mitochondrial translocation of Bax, down-regulation of
antiapoptotic Bcl-2 and Bcl-XL, increase in intracellular Ca2+,
m depolarization, calpain activation, caspase-3 activation,
and PS exposure via extracellular signal-regulated protein
kinase (ERK) signaling pathway
Aspirin As antiplatelet agents to treat thrombotic occlusion of coronary
and cerebral arteries, and vascular grafts; administered
immediately after MI to reduce the risk of another attack and
revive the cardiac tissue
m depolarization, PS exposure, caspase-3 activation, and
platelet shrinkage
Arsenic trioxide Treatment of acute promyelocytic leukemia, lymphoma,
hepatocellular carcinoma, myelodysplastic syndrome
m  depolarization, up-regulation of Bax and down-regulation
of Bcl-2 and Bcl-XL, caspase-3 activation, and PS exposure via
JNK activation
Dibucaine Local anesthetic used as a spinal and topical anesthesia m depolarization, Bax and Bak up-regulation, Bcl-2 and
Bcl-XL down-regulation, caspase-3 activation, and PS
externalization
Resveratrol Antioxidant, cardioprotective, cancer preventive, anti-diabetic,
neuroprotective, anti-inflammatory effects
Cleavage of Bid into tBid, translocation of Bax into
mitochondria, release of cytochrome c from mitochondria,
m depolarization, activation of caspases-8, -9 and -3,
cytoskeleton remodeling, cell shrinkage, and PS externalization
Thymoquinone Antioxidant, cardioprotective, anti-cancer, hepatoprotective,
renoprotective, analgesic and anticonvulsant properties
Stimulates platelet apoptosis via GPCR-activated PI3K
pathway involving increase in intracellular Ca2+, m
depolarization, ceramide formation, caspase 3 activation, cell
shrinkage and PS exposure
Gossypol Anti-cancer effects Up-regulation of Bax, coated platelet formation, m
depolarization, PS exposure, and release of MPs
Andrographolide Anticancer, antioxidant and hepatoprotective properties m depolarization, activation of caspases-3 and -8, cleavage
of Bid into tBid
Sesamol Antiaging, antioxidant, hepatoprotective, neuroprotective,
antiinflammatory, chemoprotective, chondroprotective and
anti-arthritic properties
Elevated intracellular ROS particularly H2O2 and Ca2+, m
depolarization, cytochrome c release, activation of caspases-9
and -3, and PS externalization
Melatonin Managing jet lag, insomnia, blood pressure, fatigue, ovarian
physiology and fibromyalgia
Elevated intracellular ROS and Ca2+, m depolarization,
cytochrome c release, activation of caspases-9 and -3, protein
phosphorylation, PS externalization, and loss of platelet
viability
Carmustine Hodgkin’s and non-Hodgkin’s lymphoma, brain cancers and m depolarization, up-regulation of Bax, down-regulation of
d
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smultiple myeloma
iabetic patients etc. Thus, the single-dimensional treatment
egimen of targeting the symptoms is itself questionable, and
ather a holistic approach of healing is required in today’s
ime. In this perspective, the potential use of plant-derived
iologicals as auxiliary therapy along with the normal
reatment regimen could be considered. One more approach,
hich is rather futuristic, is to exploit MPs in disease man-
gement. It is a known fact that platelets produce different
ypes of MPs in response to different stimuli under varying
hysiological and pathological conditions. These PMPs vary
n their composition and thereby in their effect produced
n the target cells as well. Therefore, with the backgroundPlease cite this article in press as: Thushara RM, et al. Biologicals,
Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.11.0
f recent research activities on personalized medicines, we
ypothesize that the future of MPs would be their application
n disease management. The negative side of MPs if it can
p
f
[Bcl-2 and caspase-3 activation
e said so, can be exploited in a positive manner by means
f generating tailor-made MPs. If MPs could be generated
y incorporating specific effector molecules and as well as
urface antigens, which can target a specific set of cells or
issues, it could turn out to be a revolution in the new-age
isease management. By virtue of their small size, the
ariety of cytosolic fractions that they can carry and their
ccessibility to the biological system so as to bring about
 wide array of pathophysiological effects, makes them
otential candidates in the future of therapeutic stratagem.
urthermore, it is a known fact that platelets are abundant
ources of factors associated with wound healing such as platelet apoptosis and human diseases: An outlook. Crit Rev
02
latelet-derived growth factor (PDGF), transforming growth
actor (TGF) and vascular endothelial growth factors (VEGF)
56]. It is the basis of PRP therapy for tissue repair and it
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s being used in the treatment of osteoarthritis, bone repair
nd regeneration, tendinitis, nerve injury, cardiac muscle
njury, etc. However, it has been reported that in stored PRP
ven under standard banking conditions, platelets eventually
ose their activity and tend to undergo apoptosis [57]. Thus,
t is obvious that there will be an increased concentration
f MPs in stored platelet concentrates, which might lead
o secondary complications if used for treatment. Hence,
ore research is required in this direction and the option of
ailor-made MPs instead of PRP therapy could be explored.
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